Specific risk appears to be low, except in those patients who are being treated with corticosteroids or infliximab for the purpose of an ICI-induced immune-related adverse event (irAE)
v2.2
Specific risk appears to be low, except in those patients who are being treated with corticosteroids or infliximab for the purpose of an ICI-induced immune-related adverse event (irAE)